Skip to main content
Equibles
ABOS logo

ABOS · Acumen Pharmaceuticals, Inc. · Metrics

Track ABOS — free

Use ABOS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABOS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.98 -0.08 (-3.88%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, management has concluded that substantial doubt exists regarding our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$143.19M
Shares
72.32M
Volume · Oct 23 541.79K Avg daily vol (3M) 458.35K

ABOS metrics

71 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.98
Market cap
$143.19M

Price action

20 metrics
Price change (1W)
+17.2%
Price change (30D)
-11.4%
Price change (3M)
-7.0%
Price change (6M)
-23.0%
Price change (YTD)
-6.2%
Price change (1Y)
-6.2%
Trailing year
Price change (5Y)
-86.2%
52-week high
$3.37
52-week low
$1.55
Change from 52-week high
-41.2%
Change from 52-week low
+27.7%
Annualized volatility
80.6%
Annualized volatility (3M)
75.9%
Beta
2.0
RSI (14D)
43.2
Price vs SMA 50
-21.0%
Price vs SMA 200
-20.8%
Avg volume (3M)
458,348
Relative volume
1.2
Average dollar volume
$1.10M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
72.32M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.5
reciprocal yield 39.4%
FCF yield
-63.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-72.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-26
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$105.42M
Net income (TTM)
−$105.04M
Trailing 12 months
Diluted EPS (TTM)
$-1.62
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.64
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.63
Operating cash flow per diluted share (TTM)
$-1.45
Free cash flow per diluted share (TTM)
$-1.45
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.35
Stock compensation per diluted share (TTM)
$0.15
Book value per share
$1.16

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+19.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-183.4%
Return on assets
-90.5%
Debt / equity
0.6
Current ratio
2.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$91.79M
Quick ratio
2.5
Interest coverage
-24.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$78.63M
Latest balance sheet
Cash & equivalents
$59.44M
Total assets
$116.01M
Total debt
$31.57M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$91.79M
Capital expenditures (TTM)
$0
R&D (TTM)
$86.79M
SG&A (TTM)
—
Stock compensation (TTM)
$9.80M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
96
13F filer change QoQ
+11
Institutional ownership
66.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
46.9%
Private-fund adviser ownership
46.9%
Active holders' share change QoQ
-5.6%
Holder tenure
15.6
Price vs estimated holder cost
-60.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.4%

Short interest

3 metrics
Short interest
4.3%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1576885 CUSIP 00509G209 13F (30d) 8 filings 8 filers Visit website Investor relations